Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Structural Heart Disease
•
Preventive Cardiology
Do you favor mechanical AVR over bioprosthetic AVR in patients 60 years or younger undergoing cardiac surgery based on recent data from the STS-ACSD suggesting a survival benefit with mechanical AVR?
Bowdish, et al.
Related Questions
Are there any indications for valve intervention in asymptomatic patients with moderate AS?
Is moderate-intensity statin plus ezetimibe just as effective as high-intensity statin monotherapy in preventing major cardiovascular events?
How do you counsel patients with metabolic syndrome who decline statin therapy and have low coronary calcium scores regarding their long-term CVD risk?
How would you approach the risk-benefit ratio of systemic anticoagulation in certain clinical scenarios such as atrial fibrillation or LV thrombus when a patient's history is also notable for type B aortic dissection or other aortic pathology such as aortic ulceration?
What is a reasonable timeline for a left heart catheterization in a patient with newly diagnosed severe LV systolic dysfunction of unclear etiology and without an ACS presentation?
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
What would be your next diagnostic test of choice for a patient with findings concerning for silent ischemia on noninvasive functional testing in the absence of chest pain?
What is your approach to determining the safety, appropriateness, and timing of SPECT or PET MPI in patients admitted with NSTEMI and who remain chest pain-free and hemodynamically stable?
What is the optimal anti-platelet/anticoagulant strategy and duration following a left atrial appendage occlusion with a watchmen device and is a CTA good enough to assess if the device is well seated and without any peri device leaks?
What do you make of the results of the recent phase 2 RCT on Zerlasiran in terms of effectiveness at reducing lipoprotein (a) levels and the timing for when this will become readily available for patients who may benefit the most from it?
